Yesterday, $Harrow Health Inc(HROW)$ CEO Mark Baum spoke at Cantor's conference and he couldn't have been more bullish. Here is everything you need to know. 1. The $250M revenue quarter for 2027. This goal has been reiterated since 2025. Put it against Q4 2025's $89.1M, and the growth target seems difficult. The business has to nearly triple. If they achieve this, the stock will rally. 2. Under-promise and over-deliver is the new motto. Baum is changing strategy because Harrow underperformed expectations in H1 2026, when VEVYE pricing changes dragged first-half revenue to about $115M. A lower bar in the future protects the stock from another miss and earns back some credibility. 3. H2 2026 must deliver. Harrow booked roughly $115M in the first hal